REGNRegeneron PharmaceuticalsSigning up patients
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 904 (planned)
- Started
- Dec 13, 2023
- Main results expected
- Mar 30, 2028
- Fully finished
- Sep 12, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose Limiting Toxicities (DLTs)
Measured over: Up to 35 days
Incidence of Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to 2 years
Severity of TEAEs
Measured over: Up to 2 years
Progression Free Survival (PFS), assessed by Independent Central Review (ICR)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06091865 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC